Literature DB >> 15004010

Removal of B-domain sequences from factor V rather than specific proteolysis underlies the mechanism by which cofactor function is realized.

Raffaella Toso1, Rodney M Camire.   

Abstract

Factor V, the precursor of factor Va, circulates in plasma with little or no procoagulant activity. Activity is generated following limited proteolysis indicating that the conversion of factor V to factor Va results in appropriate structural changes, which impart cofactor function. We have produced recombinant partial B-domain-truncated derivatives of factor V (FV(des811-1491) and FV(des811-1491) with Arg(709) and Arg(1545) mutated to Gln) to investigate whether discrete proteolysis within the B-domain followed by a conformational transition is responsible for activation. Direct binding fluorescence measurements as well as steady-state kinetic assays were employed to assess the ability of these factor V derivatives to assemble and function in prothrombinase. In contrast to human factor V, single-chain B-domain-truncated factor V bound to FXa membranes with an affinity that was identical to factor Va. Additionally, it was found that, once this modified derivative was assembled in prothrombinase, it functioned in an equivalent manner to factor Va. Taken together these data support the hypothesis that proteolysis within the B-domain of factor V, although necessary, is incidental to the mechanism by which cofactor function is realized. Instead, our results are more consistent with the interpretation that proteolytic activation of factor V simply eliminates steric and/or conformational constraints contributed by the B-domain that otherwise interfere with discrete binding interactions that govern the eventual function of factor Va.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15004010     DOI: 10.1074/jbc.M402107200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

1.  Ratcheting of the substrate from the zymogen to proteinase conformations directs the sequential cleavage of prothrombin by prothrombinase.

Authors:  Elsa P Bianchini; Steven J Orcutt; Peter Panizzi; Paul E Bock; Sriram Krishnaswamy
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-08       Impact factor: 11.205

2.  Venom factor V from the common brown snake escapes hemostatic regulation through procoagulant adaptations.

Authors:  Mettine H A Bos; Michael Boltz; Liam St Pierre; Paul P Masci; John de Jersey; Martin F Lavin; Rodney M Camire
Journal:  Blood       Date:  2009-04-13       Impact factor: 22.113

3.  Membrane-dependent interaction of factor Xa and prothrombin with factor Va in the prothrombinase complex.

Authors:  Shabir H Qureshi; Likui Yang; Chandrashekhara Manithody; Alireza R Rezaie
Journal:  Biochemistry       Date:  2009-06-09       Impact factor: 3.162

4.  Restoring the procofactor state of factor Va-like variants by complementation with B-domain peptides.

Authors:  Matthew W Bunce; Mettine H A Bos; Sriram Krishnaswamy; Rodney M Camire
Journal:  J Biol Chem       Date:  2013-09-06       Impact factor: 5.157

5.  Restricted active site docking by enzyme-bound substrate enforces the ordered cleavage of prothrombin by prothrombinase.

Authors:  Ayse Hacisalihoglu; Peter Panizzi; Paul E Bock; Rodney M Camire; Sriram Krishnaswamy
Journal:  J Biol Chem       Date:  2007-09-11       Impact factor: 5.157

6.  Meizothrombin is an unexpectedly zymogen-like variant of thrombin.

Authors:  Harlan N Bradford; Sriram Krishnaswamy
Journal:  J Biol Chem       Date:  2012-07-19       Impact factor: 5.157

Review 7.  Spatiotemporal regulation of coagulation and platelet activation during the hemostatic response in vivo.

Authors:  L Ivanciu; T J Stalker
Journal:  J Thromb Haemost       Date:  2015-10-23       Impact factor: 5.824

8.  Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant.

Authors:  A von Drygalski; T J Cramer; V Bhat; J H Griffin; A J Gale; L O Mosnier
Journal:  J Thromb Haemost       Date:  2014       Impact factor: 5.824

9.  The role of thrombin exosites I and II in the activation of human coagulation factor V.

Authors:  Kenneth Segers; Björn Dahlbäck; Paul E Bock; Guido Tans; Jan Rosing; Gerry A F Nicolaes
Journal:  J Biol Chem       Date:  2007-09-18       Impact factor: 5.157

10.  Recombinant canine B-domain-deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model.

Authors:  Denise E Sabatino; Christian Furlan Freguia; Raffaella Toso; Andrey Santos; Elizabeth P Merricks; Haig H Kazazian; Timothy C Nichols; Rodney M Camire; Valder R Arruda
Journal:  Blood       Date:  2009-09-21       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.